%0 Journal Article
%T Clinical outcomes of patients with mut-type methylmalonic acidemia identified through expanded newborn screening in China.
%A Ling S
%A Wu S
%A Shuai R
%A Yu Y
%A Qiu W
%A Wei H
%A Yang C
%A Xu P
%A Zou H
%A Feng J
%A Niu T
%A Hu H
%A Zhang H
%A Liang L
%A Wang Y
%A Chen T
%A Xu F
%A Gu X
%A Han L
%J Hum Genomics
%V 18
%N 1
%D 2024 Jul 29
%M 39075538
%F 6.481
%R 10.1186/s40246-024-00646-0
%X BACKGROUND: Isolated methylmalonic acidemia, an autosomal recessive disorder of propionate metabolism, is usually caused by mutations in the methylmalonyl-CoA mutase gene (mut-type). Because no universal consensus was made on whether mut-type methylmalonic acidemia should be included in newborn screening (NBS), we aimed to compare the outcome of this disorder detected by NBS with that detected clinically and investigate the influence of NBS on the disease course.
METHODS: In this study, 168 patients with mut-type methylmalonic acidemia diagnosed by NBS were compared to 210 patients diagnosed after disease onset while NBS was not performed. Clinical data of these patients from 7 metabolic centers in China were analyzed retrospectively, including initial manifestations, biochemical metabolites, the responsiveness of vitamin B12 therapy, and gene variation, to explore different factors on the long-term outcome.
RESULTS: By comparison of the clinically-diagnosed patients, NBS-detected patients showed younger age at diagnosis, less incidence of disease onset, better responsiveness of vitamin B12, younger age at start of treatment, lower levels of biochemical features before and after treatment, and better long-term prognosis (Pā<ā0.01). Onset of disease, blood C3/C2 ratio and unresponsiveness of vitamin B12 were more positively associated with poor outcomes of patients whether identified by NBS. Moreover, the factors above as well as older age at start of treatment were positively associated with mortality.
CONCLUSIONS: This research highly demonstrated NBS could prevent major disease-related events and allow an earlier treatment initiation. As a key prognostic factor, NBS is beneficial for improving the overall survival of infants with mut-type methylmalonic acidemia.